Bone quality: What is it and how is it measured?

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 4, 2006, Pages 579-585

  Compston, Juliet ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Bone quality; Bone strength; Fracture; Microarchitecture; Mineralisation; Turnover

Indexed keywords

EID: 33751233831     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000400003     Document Type: Review

References (43)

1. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004;34:599-604.
2. Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 1969;3:211-37.
3. Eventov I, Frisch B, Cohen Z, Hammel I. Osteopenia, hematopoiesis, and bone remodelling in iliac crest and femoral biopsies: a prospective study of 102 cases of femoral neck fractures. Bone 1991;12:1-6.
4. Croucher PI, Garrahan NJ, Compston JE. Assessment of cancellous bone structure: comparison of strut analysis, trabecular bone pattern factor and marrow space star volume. J Bone Miner Res 1996;11:955-61.
5. Jårvinen TLN, Sievånen H, Jokihaara J, Einhorn TA. Revival of bone strength: the bottom line. J Bone Miner Res 2005;20:717-20.
6. Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 1997;21:373-8.
7. Paschalis EP, Verdelis K, Doty SB, Boskey AL, Mendelsohn R, Yamauchi M. Spectroscopic characterization of collagen cross-links in bone. J Bone Miner Res 2001;16:1821-8.
8. Wang XF, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone 2002;31:1-7.
9. Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fhyrie DP. Influence of non-enzymatic glycation on biomechanical properties of cortical bone. Bone 2001;28:1-7.
10. Paschalis EP, Shane E, Lyritis G, Skarantavos G, Mendelsohn R, Boskey AL. Bone fragility and collagen cross-links. J Bone Miner Res 2004;19:2000-4.
11. Burr DB. Targeted and non-targeted remodelling. Bone 2002;30:2-4.
12. Boivin G, Duriez J, Chapuy M-C, Flautre B, Hardouin P, Meunier PJ. Relationship between bone fluoride content and histologic evidence of calcification defects in osteoporotic women treated long term with sodium fluoride. Osteoporos Int 1993;3:204-8.
13. Glorieux FH, Bishop NJ, Travers R. Bone histomorphometric analysis in osteogenesis imperfecta type IV: evidence for three discrete forms. Bone 1996;19:142S.
14. Grant SFA, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH. Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet 1996;14:1-6.
15. Compston J. Osteoporosis after liver transplantation. Liver Transpl 2003;9:321-30.
16. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton III LJ, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:893-9.
17. Weinstein RS. Perspective. True Strength. J Bone Miner Res 2000;15:621-5.
18. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-21.
19. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999;33:287-93.
20. Mellström DD, Sorensen OH, Goemare S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8.
21. Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.
22. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk F, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.
23. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
24. Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ, et al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000;15:754-62.
25. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Treschel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
26. Recker RR, Weinstein RS, Chesnut CH, Schimmer RC, Mahoney P, Hughes C, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004;15:231-7.
27. Eriksen EF, Melsen F, Sod E, Barton I, Chines A. Effects of risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002;31:620-5.
28. Vedi S, Skingle SJ, Compston JE. The effects of long-term hormone replacement therapy on bone remodelling in postmenopausal women. Bone 1996;19:535-9.
29. Prestwood KM, Gunness M, Muchmore DB, Lu Y, Wong M, Raisz LG. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-202.
30. Riggs BL, Melton III LJ. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002;17:11-4.
31. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6.
32. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C. Six and twelve-month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001;12:922-30.
33. Melton III LJ, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083-91.
34. Vedi S, Croucher PI, Garrahan NJ, Compston JE. Effects of hormone replacement therapy on cancellous bone microstructure in postmenopausal women. Bone 1996;19:69-72.
35. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 2003;73:423-32.
36. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004;34:736-46.
37. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001;29:185-91.
38. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53.
39. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-41.
40. Boivin G, Chavassieux PM, Santora AC, Yates AJ, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralisation of bone tissue in osteoporotic women. Bone 2000;27:687-94.
41. Boivin G, Vedi S, Purdie DW, Compston JE, Meunier PJ. Influence of estrogen therapy at conventional and high doses on the degree of mineralisation of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women. Bone 2005;36:562-7.
42. Roschger P, Grabner BM, Messmer P, Dempster DW, Cosman F, Nieves J, et al. Influence of intermittent PTH treatment on mineral distribution in the human ilium: a paired biopsy study before and after treatment. J Bone Miner Res 2001;16:S179.
43. Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Tsouderos Y, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S12911) administration. J Bone Miner Res 1996;11:1302-11.